Page 2147 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 126 Molecular Basis of Blood Coagulation 1905.e3

104. Lenk H, Nilsson IM, Holmberg L, et al: Frequency of different types of 129. Lawson JH, Kalafatis M, Stram S, et al: A model for the tissue factor
von Willebrand’s disease in the GDR. Acta Med Scand 224:275, 1988. pathway to thrombin. I. An empirical study. J Biol Chem 269:23357,
105. Pottinger BE, Read RC, Paleolog EM, et al: von Willebrand factor is 1994.
an acute phase reactant in man. Thromb Res 53:387, 1989. 130. Gailani D, Broze GJ, Jr: Factor XI activation in a revised model of blood
106. Blann AD: von Willebrand factor antigen as an acute phase reactant coagulation. Science 253:909, 1991.
and marker of endothelial cell injury in connective tissue diseases: a 131. Wiggins RC, Cochrane CC: The autoactivation of rabbit Hageman
comparison with CRP, rheumatoid factor, and erythrocyte sedimenta- factor. J Exp Med 150:1122, 1979.
tion rate. Z Rheumatol 50:320, 1991. 132. Silverberg M, Dunn JT, Garen L, et al: Autoactivation of human
107. Stevens TR, James JP, Simmonds NJ, et al: Circulating von Willebrand Hageman factor. Demonstration utilizing a synthetic substrate. J Biol
factor in inflammatory bowel disease. Gut 33:502, 1992. Chem 255:7281, 1980.
108. Ates E, Bakkaloglu A, Saatci U, et al: von Willebrand factor antigen 133. Schmaier AH: Assembly, activation, and physiologic influence of the
compared with other factors in vasculitic syndromes. Arch Dis Child plasma kallikrein/kinin system. Int Immunopharmacol 8:161, 2008.
70:40, 1994. 134. Mandle RJ, Colman RW, Kaplan AP: Identification of prekallikrein and
109. Hathaway WE, Belhasen LP, Hathaway HS: Evidence for a new plasma high-molecular-weight kininogen as a complex in human plasma. Proc
thromboplastin factor. I. Case report, coagulation studies and physico- Natl Acad Sci USA 73:4179, 1976.
chemical properties. Blood 26:521, 1965. 135. Scott CF, Silver LD, Schapira M, et al: Cleavage of human high
110. Hoak JC, Swanson LW, Warner ED, et al: Myocardial infarction associ- molecular weight kininogen markedly enhances its coagulant activity.
ated with severe factor-XII deficiency. Lancet 2:884, 1966. Evidence that this molecule exists as a procofactor. J Clin Invest 73:954,
111. Colman RW, Bagdasarian A, Talamo RC, et al: Williams trait. Human 1984.
kininogen deficiency with diminished levels of plasminogen proactiva- 136. Scott CF, Silver LD, Purdon AD, et al: Cleavage of human high
tor and prekallikrein associated with abnormalities of the Hageman molecular weight kininogen by factor XIa in vitro. Effect on structure
factor-dependent pathways. J Clin Invest 56:1650, 1975. and function. J Biol Chem 260:10856, 1985.
112. Biggs R, Douglas AS, Macfarlane RG, et al: Christmas disease: a 137. Rosenberg RD, Damus PS: The purification and mechanism of action
condition previously mistaken for haemophilia. Br Med J 2:1378, of human antithrombin-heparin cofactor. J Biol Chem 248:6490, 1973.
1952. 138. Perry DJ, Carrell RW: Molecular genetics of human antithrombin
113. Owen CA, Jr, Cooper T: Parahemophilia. AMA Arch Intern Med deficiency. Hum Mutat 7:7, 1996.
95:194, 1955. 139. Harper PL, Luddington RJ, Daly M, et al: The incidence of dys-
114. Telfer TP, Denson KW, Wright DR: A new coagulation defect. Br J functional antithrombin variants: four cases in 210 patients with
Haematol 2:308, 1956. thromboembolic disease. Br J Haematol 77:360, 1991.
115. Hoyer LW: Molecular pathology and immunology of factor VIII 140. Casu B, Oreste P, Torri G, et al: The structure of heparin oligosac-
(hemophilia A and factor VIII inhibitors). Hum Pathol 18:153, 1987. charide fragments with high anti-(factor Xa) activity containing the
116. Roberts HR, Escobar MA: Inherited disorders of prothrombin conver- minimal antithrombin III-binding sequence. Chemical and 13C
sion. In Colman RW, Marder VJ, Clowes AW, et al, editors: Hemostasis nuclear-magnetic-resonance studies. Biochem J 197:599, 1981.
and thrombosis – Basic principles and clinical practice, Philadelphia, 141. Olson ST, Shore JD: Demonstration of a two-step reaction mechanism
2005, Lippincott Williams & Wilkins, p 923. for inhibition of alpha-thrombin by antithrombin III and identification
117. Woodruff RS, Sullenger B, Becker RC: The many faces of the contact of the step affected by heparin. J Biol Chem 257:14891, 1982.
pathway and their role in thrombosis. J Thromb Thrombolysis 32:9, 142. Olson ST, Bjork I, Shore JD: Kinetic characterization of heparin-
2011. catalyzed and uncatalyzed inhibition of blood coagulation proteinases
118. Bone R: Sepsis and multiple organ failure: consensus and controversy. by antithrombin. Methods Enzymol 222:525, 1993.
In Lamy M, Thijs LG, editors: Mediators of sepsis, New York, 1992, 143. O’Reilly MS, Pirie-Shepherd S, Lane WS, et al: Antiangiogenic activ-
Springer-Verlag, p 3. ity of the cleaved conformation of the serpin antithrombin. Science
119. Colman RW: Contact activation pathway: inflammatory, fibrinolytic, 285:1926, 1999.
anticoagulant, antiadhesive and antiangiogenic activites. In Colman 144. Novotny WF, Girard TJ, Miletich JP, et al: Purification and character-
RW, Hirsh J, Marder VJ, et al, editors: Hemostasis and thrombosis - Basic ization of the lipoprotein-associated coagulation inhibitor from human
principles and clinical practice, Philadelphia, 2001, Lippincott Williams plasma. J Biol Chem 264:18832, 1989.
& Wilkins, p 103. 145. Bajaj MS, Kuppuswamy MN, Saito H, et al: Cultured normal human
120. Renne T, Pozgajova M, Gruner S, et al: Defective thrombus formation hepatocytes do not synthesize lipoprotein-associated coagulation inhibi-
in mice lacking coagulation factor XII. J Exp Med 202:271, 2005. tor: evidence that endothelium is the principal site of its synthesis. Proc
121. Kleinschnitz C, Stoll G, Bendszus M, et al: Targeting coagulation Natl Acad Sci USA 87:8869, 1990.
factor XII provides protection from pathological thrombosis in cerebral 146. Broze GJ, Jr, Lange GW, Duffin KL, et al: Heterogeneity of plasma
ischemia without interfering with hemostasis. J Exp Med 203:513, tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 5:551, 1994.
2006. 147. Olivera BM: E.E. Just lecture, 1996. Conus venom peptides, recep-
122. Schousboe I: Pharmacological regulation of factor XII activation may tor and ion channel targets, and drug design: 50 million years of
be a new target to control pathological coagulation. Biochem Pharmacol neuropharmacology. Mol Biol Cell 8:2101, 1997.
75:1007, 2008. 148. Sanders NL, Bajaj SP, Zivelin A, et al: Inhibition of tissue factor/factor
123. Schmaier AH: Plasma contact activation: a revised hypothesis. Biol Res VIIa activity in plasma requires factor X and an additional plasma
31:251, 1998. component. Blood 66:204, 1985.
124. Rojkjaer R, Hasan AA, Motta G, et al: Factor XII does not initiate 149. Lesnik P, Vonica A, Guerin M, et al: Anticoagulant activity of tissue
prekallikrein activation on endothelial cells. Thromb Haemost 80:74, factor pathway inhibitor in human plasma is preferentially associated
1998. with dense subspecies of LDL and HDL and with Lp(a). Arterioscler
125. Kannemeier C, Shibamiya A, Nakazawa F, et al: Extracellular RNA Thromb 13:1066, 1993.
constitutes a natural procoagulant cofactor in blood coagulation. Proc 150. Broze GJ, Jr: Tissue factor pathway inhibitor. Thromb Haemost 74:90,
Natl Acad Sci USA 104:6388, 2007. 1995.
126. Muller F, Renne T: Platelet polyphosphates: the nexus of primary and 151. Sandset PM: Tissue factor pathway inhibitor (TFPI)–an update.
secondary hemostasis. Scand J Clin Lab Invest 71:82, 2011. Haemostasis 26:154, 1996.
127. Rapaport SI, Proctor RR, Patch MJ, et al: The mode of inheritance of 152. Lindahl AK: Tissue factor pathway inhibitor: from unknown coagula-
PTA deficiency: evidence for the existence of major PTA deficiency and tion inhibitor to major antithrombotic principle. Cardiovasc Res 33:286,
minor PTA deficiency. Blood 18:149, 1961. 1997.
128. Sidi A, Seligsohn U, Jonas P, et al: Factor XI deficiency: detection and 153. Schwartz AL, Broze GJ, Jr: Tissue factor pathway inhibitor endocytosis.
management during urological surgery. J Urol 119:528, 1978. Trends Cardiovasc Med 7:234, 1997.